Barcha huquqlar himoyalangan.
0.00
0.00 (0.00%)
There is no data to display
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales Procept BioRobotics set aggressive revenue targets while a internal pricing change was already undercutting realized sales
Procept BioRobotics reported one set of numbers to investors -- the actual figures told a different story NEW YORK, March 25, 2026 /PRNewswire/ -- Investors in Procept BioRobotics (NASDAQ: PRCT) lost more than 15% of their investment value after the Company disclosed financial results that diverged sharply from the figures management had presented. Those who suffered losses are encouraged to submit their information here.
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
